Article

Video blog: Test could spare some DCIS patients from radiation

Author(s):

Debu Tripathy

Dr. Debu Tripathy discusses how a test, a variation of the Oncotype DX test, could help physicians decide on radiation therapy for their patients diagnosed with ductal carcinoma in situ (DCIS).

Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
1 expert is featured in this series.
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
1 expert is featured in this series.
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Related Content
Illustration of red blood cells.
January 10th 2025

P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia

Ryan Scott
P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Gai Terrell / Redferns via Getty Images
January 10th 2025

Peter Yarrow Dies of Bladder Cancer, Dick Vitale Cleared for ESPN Return and More

Alex Biese
From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, here is this week’s news.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
An image of sarcoma written out on a tablet.
January 9th 2025

FDA Grants BTD to the ADC GSK’227 in Relapsed/Refractory Osteosarcoma

Ryan Scott
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with relapsed/refractory osteosarcoma.
Image of gastric gastrointestinal stromal tumors.
January 9th 2025

Laparoscopic Wedge and Endoscopic Resection Are Safe, Feasible in Gastric GISTs

Ryan Scott
Both laparoscopic wedge and endoscopic resection are safe and feasible treatment approaches for patients with gastric gastrointestinal stromal tumors.